Can a targeted combo spare early breast cancer patients from harsh chemo?
NCT ID NCT07271992
First seen Jan 08, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests a two-drug combination (sacituzumab govitecan plus tislelizumab) as a gentler pre-surgery treatment for people with early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors enough to avoid standard chemotherapy, and to identify which patients benefit most based on specific markers. About 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.